Earnings call transcript: Crawford & Company tops Q3 EPS view, shares edge up

Crawford & Company reported Q3 2026 non-GAAP EPS of $0.37, 27.6% above the $0.29 consensus; revenue was reported at $313.7 million versus a $327.41 million forecast, while the earnings-call figures showed revenue before reimbursements of $321.6 million, essentially flat year over year. Net income rose to $15 million from $12.4 million, and non-GAAP operating margin expanded to 9% from 8.3%, but softer claims activity and expected lower international catastrophe work are headwinds for Q4. Shares rose 1.89% in premarket trading to $12.42; the company paid a $0.08 quarterly dividend and repurchased shares.

Analysis

The quarter supports a margin-resilience thesis, not yet a demand-reacceleration thesis. Profit improvement appears partly dependent on cost control, lower corporate medical self-insurance expense and international catastrophe work nearing completion; those drivers may not repeat into Q4. Broadspire’s casualty softness is described as broad-based, so treating the revenue pressure as a single-client issue would understate the risk. Conversely, alternative-market wins could diversify demand over time, but pipeline and retention claims need to translate into segment revenue and margin before they justify a growth rerating.

The more important near-term watch item is cash conversion: receivables rose while year-to-date operating and free cash flow fell, and debt increased. Management expects receivables to normalize as catastrophe claims wind down, but that is a forecast, not proof of normalization. If collections lag, buybacks and acquisitions compete with balance-sheet flexibility even at stated leverage. Also reconcile the article’s $313.7 million revenue figure with management’s $321.6 million revenue-before-reimbursements figure before relying on the stated consensus miss; the scopes may differ.

Near term (days), the restrained reaction after a strong six-month run argues against chasing the EPS beat. Over 1–3 months, Q4 guidance and working-capital normalization are the key catalysts. Over 6–18 months, alternative-market conversion and U.S. integration could improve growth and utilization, while benign catastrophe activity and soft casualty volumes remain counterweights. The contrarian risk is that investors may over-credit a cost-led beat; the upside risk to a cautious view is that new programs convert faster than expected.

Key Decisions for Investors

• CRD.A: Do not chase the post-earnings move; consider trimming into strength rather than adding until organic revenue and cash conversion confirm the earnings improvement. The stock’s recent run and proximity to its 52-week high leave less room for a merely cost-driven beat to surprise positively.
• Use the next quarter as a confirmation point, not a forecast extrapolation: monitor Broadspire revenue and operating margin, alternative-market wins reaching reported results, and billed/unbilled receivables alongside operating cash flow. Improving cash conversion with stable Broadspire margins would weaken the cautious thesis.
• Treat management’s receivables-normalization expectation as an alert, not an established outcome. Reassess if receivables keep rising or free cash flow remains weak as international catastrophe work runs off; that would challenge the buyback/acquisition optionality narrative.
• Verify the revenue figure and reporting scope against the company filing and consensus definition before positioning on the sales miss. A material apples-to-apples miss would strengthen the demand concern; a scope mismatch would make the headline miss less informative.